The Goodyear & Tire Rubber Company

Nektar Therapeutics

Baxalta Gmbh

Massachusetts Institute of Technology

Baxter International Inc.

Baxter Healthcare Sa

Cabot Corporation

Symbiocelltech, LLC

Schlumberger Canada Limited

Ping Zhang

Mary J Bossard

Michael David Bentley

Paul Harry Sandstrom

Joseph Kevin Hubbell

Harold Zappe

Peter Turecek

Zhihao Fang

Eric Sean Castner

Katalin Varadi

Lei Zheng

Friedrich Scheiflinger

Juergen Siekmann

Keith Carl Trares

Robert Anthony Neubauer

Herbert Gritsch

Gayle Stephenson

Klavs F Jensen

Jie Chen

Robert Allen Losey

Junling Zhao

Timothy F Jamison

Allan Stuart Myerson

Kuo-Chih Hua

Wen-Liang Hsu

David John Zanzig

James A Belmont

Ramendra Nath Majumdar

John Joseph Andre Verthe

Andrea Adamo

Marc Weydert

Shingo Futamura

Aaron Scott Puhala

Hanspeter Rottensteiner

Sean M Culbertson

George Frank Balogh

Alfred Weber

Deborah H Charych

Gary Robert Burg

William Paul Francik

Joseph John Kulig

Roger Neil Beers

Xiaoping Yang

Kenneth Allen Bates

Sun-Lin Chen

Bart Wakefield Kimble

Feng Anne Xie

Stacy Mitchell

Jean-Christophe Monbaliu

David R Snead

Robert Bernard Nelson

Mohsen Behnam

Nopphon Weeranoppanant

Torsten Stelzer

Shin Yee Wong

Eve Marie Revalor

Christof Westenfelder

Steven Wayne Cronin

C Simone Jude-Fishburn

Vijay R Tirumala

Thomas Charles Lippello, Iii

Yujun Wang

James Joseph Golden

Federico Villalpando-Paez

Heinz Anderle

Xiaofeng Liu

Alyson M Christopher

Dennis G Fry

Dawei Sheng

Cherie F Ali

Haim Moskowitz

Eddy Dong-Rong Pan

Mark Alan Keto

Rebecca Lee Dando

Larry Alan Kraus

Anna L Gooch

Christine Taylor Brew

Peter Benedict Kirk

Oliver W Tassinari

Douglas Andrew Till

Steven O Roczniak

Zhuma Hu

Peiwen Kuo Brewer

Cynthia Nelson, Legal Representative

Elizabeth Louise Minamitani

Greggory C Smith

Gerald Schrenk

Christine Brew

Peter Benecict Kirk

Eldad Haber

Elizabeth Minamitani

Paul Harry Sanstrom

The instant disclosure provides a long acting IL-15 receptor agonist, related compositions and methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity.

Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients, are provided. Certain of the systems and methods described herein are capable of manufacturing multiple chemical products without the need to fluidically connect or disconnect unit operations when switching from one making chemical product to making another chemical product.

Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients

Described are Neo-Islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating Neo-Islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells; on a surface that promotes the formation of cell clusters. Also described are methods of treating a subject, the methods comprising: providing to the subject Neo-Islets described herein. Additionally described are methods of treating a subject suffering from Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance by providing to the subject Neo-Islet as described herein. Additionally described are methods of treatment in which intraperitoneal administration of islet-sized Neo-Islets composed of high numbers of mesenchymal stem cells and cultured islet cells, durably and reversibly treats, without hypoglycemia, both streptozotocin-induced and spontaneous Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance.

Neo-Islets comprising stem and islet cells and treatment of diabetes mellitus therewith

Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.

Method of making a water-soluble polymer-factor VIII moiety conjugate

This invention discloses a tire having enhanced wet traction and ice traction characteristics. These tires are comprised of a generally toroidal-shaped carcass with an outer circumferential tread, two spaced beads, at least one ply extending from bead to bead and sidewalls extending radially from and connecting said tread to said beads, wherein said tread is adapted to be ground-contacting, wherein the tread includes at least one circumferential groove which separates circumferential ribs, each circumferential groove having two sides and a base therebetween, and wherein the sides of each circumferential groove are comprised of a rubbery composition that includes silicate microflakes which are substantially aligned in an orientation which is parallel with the sides of the grooves.

Tire containing silicate microflakes having enhanced traction characteristics

A compounded elastomer comprising an elastomeric resin, a first carbon black, and a second carbon black different from the first carbon black. The second carbon black is a partially crystallized carbon black having an OAN structure of greater than 120 cm/100 g and less than 200 cm/100 g, a surface energy of less than 10 mJ/mand a Raman microcrystalline planar size (L) of greater than or equal to 25 &#x212b; and less than or equal to 50 &#x212b;.

Compounded rubber having improved thermal transfer

Elastomeric compositions are described which have at least one functionalized elastomer and at least one modified filler which has adsorbed and/or attached chemical groups, such as a triazole and/or pyrazole thereon, or other modified fillers which are also described. Methods are further described to improve hysteresis and/or abrasion resistance in elastomeric compositions containing a functionalized elastomer using the modified fillers of the present invention.

Elastomeric composites containing modified fillers and functionalized elastomers

Polymer-factor VIII moiety conjugates

The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.

Polymer conjugates of therapeutic peptides

The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.

Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.

Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)

Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate

This invention discloses a tire which is comprised of a generally toroidal-shaped carcass with an outer circumferential tread, two spaced beads, at least one ply extending from bead to bead and sidewalls extending radially from and connecting said tread to said beads, wherein said tread is adapted to be ground-contacting, and wherein said tread is comprised of (1) a filler, (2) a cured rubbery polymer, and (3) core-shell particles which are comprised of (a) a crosslinked elastomeric core consisting essentially of repeat units that are derived from at least one conjugated diolefin monomer and from 15 weight percent to 30 weight percent at least one crosslinking monomer, wherein the crosslinked elastomeric core is a polymeric composition having a glass transition temperature which is within the range of &#x2212;20&#xb0; C. to 20&#xb0; C., and (b) a polymeric shell which is derived from at least one vinyl aromatic monomer, wherein the polymeric shell has a glass transition temperature which is within the range of 50&#xb0; C. to 160&#xb0; C., and wherein the weight ratio of the core to the shell is within the range of 20:1 to 7:1.

Modified gel particles and rubber composition

Growing community of inventors

Madison, AL, United States of America

Ping Zhang